<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893840</url>
  </required_header>
  <id_info>
    <org_study_id>OT-FO-01</org_study_id>
    <nct_id>NCT01893840</nct_id>
  </id_info>
  <brief_title>Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg</brief_title>
  <official_title>Effect on Blood Flow Using the FlowOx™ Device in Patients With Reduced Peripheral Circulation in the Lower Leg</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otivio AS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Research Council of Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Otivio AS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to assess the effect of negative pulsating pressure therapy on patients with impaired&#xD;
      blood flow to the leg caused by arterial disease, to see if the FlowOx device will increase&#xD;
      the blood flow to the leg in these patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% of the prescribed cycles delivered in the specified time FlowOx™-induced change in arterial leg blood flow (LBF)</measure>
    <time_frame>up to 1 hour</time_frame>
    <description>This is calculated as the difference between the blood flow during the period using FlowOx™ (middle value over a period of 5 minutes) and baseline blood flow (middle value over a period of 5 prior to using FlowOx™)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient comfort measured by asking the patient a fixed set of questions</measure>
    <time_frame>up to 1 hour</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Fitting time</measure>
    <time_frame>up to 1 hour</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Periferal Arterial Occlusive Disease, PAOD</condition>
  <arm_group>
    <arm_group_label>FlowOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5 minutes of pulsating negative pressure (10 sek og -40mmHg/7 sek of athmospheric pressure) will be Applied to the patient's leg</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FlowOx</intervention_name>
    <description>Boot-shaped pressure chamber generating pulsating negative pressure</description>
    <arm_group_label>FlowOx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written Informed Consent&#xD;
&#xD;
          -  Age 30-90 years&#xD;
&#xD;
          -  Affected foot/shoe sise less than 46 (approximate foot length less than 29.5 cm)&#xD;
&#xD;
          -  Patients with Peripheral Arterial Occlusive Disease (PAOD) grade 2,3 or 4, i.e.:&#xD;
&#xD;
               1. Clinically verified grade 2, i.e. Intermittent Claudication:&#xD;
&#xD;
                    -  Ancle-Brachial Index (ABI)less than 0.9 or&#xD;
&#xD;
                    -  Toe brachial Index (TBI) less than 0.7 or&#xD;
&#xD;
                    -  Ultrasound and/or CT/Magnetic Resonance (MR) angiography suggesting&#xD;
                       stenosis(es)and/or occlusion(s)&#xD;
&#xD;
               2. Clinically verified grade 3, i.e. Critical Limb Ischemia (CLI):&#xD;
&#xD;
                    -  ABI less than 0.4 or&#xD;
&#xD;
                    -  Toe pressure less than 30 mmHg&#xD;
&#xD;
                    -  Rest pain since at least 2 weeks or&#xD;
&#xD;
                    -  Use of analgesics for rest pain for at least 2 weeks or&#xD;
&#xD;
                    -  Ultrasound and/or CT/Magnetic Resonance (MR) angiography suggesting&#xD;
                       stenosis(es)and/or occlusion(s)&#xD;
&#xD;
               3. Clinically verified grade 4, i.e. CLI:&#xD;
&#xD;
                    -  Ischemic ulcers or gangrene/tissue loss&#xD;
&#xD;
                    -  ABI less than 0.4&#xD;
&#xD;
                    -  Toe pressure less than 30 mmHg&#xD;
&#xD;
                    -  Rest pain since at least 2 weeks or&#xD;
&#xD;
                    -  Use of analgesics for rest pain for at least 2 weeks or&#xD;
&#xD;
                    -  Ultrasound and/or CT/MR angiography suggesting stenosis(es)and/or&#xD;
                       occlusion(s)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Grade 1 PAOD&#xD;
&#xD;
          -  Incapable of consenting voluntarily&#xD;
&#xD;
          -  Fewer higher than 39 degrees Centigrade&#xD;
&#xD;
          -  Severe Chronic Obstructive Pulmonary Disease (COPD)&#xD;
&#xD;
          -  Severe heart disease such as unstable angina, severe heart failure and severe valve&#xD;
             failure&#xD;
&#xD;
          -  Severe Polyneurophathy&#xD;
&#xD;
          -  Verified Osteomyelitis other than in the Phanlanx&#xD;
&#xD;
          -  Currently treated for cancer and With a life expectancy of less than 2 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jarlis Wesche, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Akershus University Hospital</name>
      <address>
        <city>Lørenskog</city>
        <zip>N-1478</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <study_first_submitted>June 26, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <last_update_submitted>October 30, 2013</last_update_submitted>
  <last_update_submitted_qc>October 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

